FindTrial
Sign In

Short-term efficacy evaluation of Professor Liu jing in alleviating adenoidal hypertrophy in Children prospective cohort study

Real World Study: Evaluation of the Therapeutic Effect and Medication Patterns of Professor Liu Jing in Treating Adenoidal Hypertrophy in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2023000005
Enrollment
Unknown
Registered
2023-05-04
Start date
2023-05-04
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoidal Hypertrophy

Interventions

Herbal treatment group: Received Professor Liu Jing's intervention with traditional Chinese medicine for = 1 week
Western medicine treatment group:Only use Western medicine for treatment (without fixed medication), and take traditional Chinese medicine for less than one week

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 10 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the Western medical diagnostic criteria for pediatric adenoid hypertrophy ; (2) Age between 3 and 10 years old; (3) Sign the informed consent form (children aged = 8 sign independently, and children aged<8 sign on behalf of their guardians or legal representatives).

Exclusion criteria

Exclusion criteria: (1) Children with poor breathing caused by obesity, nasal polyps, deflection of nasal septum, and other reasons; (2) Severe impact on sleep, combined with severe primary systemic diseases such as heart, brain, lung, liver, kidney, and hematopoiesis; (3) Children with severe malnutrition, dysfunction, severe rickets, and mental illness; (4) Those who are unable to complete auxiliary examinations and follow-ups due to various reasons

Design outcomes

Primary

MeasureTime frame
(Visual Analogue Scale/Score;Severity grading of nasal cavity after adenoid obstruction under fiberoptic nasopharyngoscopy examination;—

Secondary

MeasureTime frame
Secondary Symptom Rating Scale;Scale for evaluating other nasal manifestations under fiberoptic nasopharyngoscope;disease specific quality of life for children with obstructive sleep apnea 18 items survey(OSA-18);—

Countries

China

Contacts

Public ContactLiu Jing

Xiyuan Hospital of China Academy of Chinese Medical Sciences

liuj032679@vip.sina.com13552494260

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026